<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03641352</url>
  </required_header>
  <id_info>
    <org_study_id>19DM17012</org_study_id>
    <nct_id>NCT03641352</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes</brief_title>
  <official_title>The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes Inadequately Controlled With D150 Plus D759, Randomized, Double-blind, Multi-center, Parallel-group, Placebo Control, Therapeutic Confirmatory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prove that the group treated with CKD-501 in combination
      added that the reduction of glycated hemoglobin superior to placebo treated group added in
      combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this phase 3 study was to evaluate the efficacy and safety of additional combined
      CKD-501 administration for 24 weeks in patient with type 2 diabetes who were nao adequately
      controlled for blood glucose by the combination of D150 and D759
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Glycosylated Hemoglobin</measure>
    <time_frame>Baseline, 24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in in Glycosylated Hemoglobin</measure>
    <time_frame>Baseline, 52weekes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fasting plasma glucose</measure>
    <time_frame>Baseline, 24weeks, 52weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c target achievement rate at 24weekes(HbA1c &lt; 6.5%, 7%)</measure>
    <time_frame>Baseline, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Total Cholesterol</measure>
    <time_frame>Baseline, 24weeks, 52weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety of CKD-501 from number of participants with adverse events</measure>
    <time_frame>Baseline, 24weeks, 52weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HOMA-IR(Homeostasis Model Assessment of Insulin Resistance)</measure>
    <time_frame>Baseline, 24weeks, 52weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HOMA-β(Homeostasis Model Assessment of β-cell function)</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QUICKI(Quantitative Insulin Check Index)</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Triglycerides</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LDL-Cholesterol</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HDL-Cholesterol</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in non-HDL-Cholesterol</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Small Dense LDL-Cholesterol</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FFA(Free Fatty Acid)</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Apo-B</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Apo-CⅢ</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Apo-AⅠ</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>CKD-501 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 0.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501 0.5mg</intervention_name>
    <description>CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759</description>
    <arm_group_label>CKD-501 0.5mg</arm_group_label>
    <other_name>Lobeglitazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 19 years and 80 years old(male or female)

          -  Type 2 diabetes mellitus

          -  The patient who has been taking oral hypoglycemic agent at least 8weeks with HbA1c 7
             to 10% at screening test

          -  BMI between 21kg/m2 and 40kg/m2

          -  C-peptide ≥ 1.0 ng/ml

          -  Agreement with written informed consent

          -  HbA1c 7 to 10% after Run-in period

        Exclusion Criteria:

          -  Type 1 diabetes mellitus or secondary diabetes mellitus

          -  Continuous or non continuous treatment(over 7 days) insulin within 3 months prior to
             screening

          -  Treatment with Thiazolidinedione(TZD) within 3 months or patient who has experience
             such as hypersensitivity reaction, serious adverse event with TZD, Biguanide

          -  Chronic(continuous over 7 days) oral or non oral corticosteroids treatment within 1
             month prior to screening

          -  Treatment with anti-obesity drugs within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun ho Yoon, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kun ho Yoon, Ph.D</last_name>
    <phone>82-2-2258-6007</phone>
    <email>yoonk@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kun ho yoon, Ph.D</last_name>
      <phone>82-2-2258-6007</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>August 19, 2018</last_update_submitted>
  <last_update_submitted_qc>August 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

